SCHEMBL3722916

SCHEMBL3722916

CC(O)c1ccc2cn[nH]c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.54
ALDH1A1 P00352 5/20 0.54
KDM4E B2RXH2 5/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
F2 P00734 1/20 0.54
NOS1 P29475 3/20 0.50
DYRK1A Q13627 2/20 0.50
METAP2 P50579 2/20 0.50
PKM P14618 1/20 0.50
HTT P42858 1/20 0.50
FGFR1 P11362 5/20 0.49
FGFR2 P21802 2/20 0.49
FGFR3 P22607 1/20 0.49
UGT2B7 P16662 1/20 0.47
CYP3A4 P08684 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30074251 0.86 ROCK2 (0.50) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL84390 0.85 MAPT (0.60) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL6181437 0.82 NOS1 (0.55) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL21510145 0.82 MAPT (0.50) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL18559548 0.82 MAPT (0.55) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL18737272 0.82 MAPT (0.50) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL12930775 0.80 MAPT (0.49) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL12930777 0.80 MAPT (0.49) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL14072852 0.79 ALDH1A1 (0.48) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL879377 0.78 MAPT (0.46) MAPTALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed
CN-101970426-A Indazolyl-, benzimidazolyl-, benzotriazolyl-substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIV HEALTH NETWORK 2011-02-09 CN disclosed
EP-2235004-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER University Health Network (CA) 2010-10-06 EP disclosed
WO-2009079767-A9 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK (CA) 2009-10-01 WO disclosed
WO-2009079767-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK (CA) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER TNNI3K, ABL1, TK1 MAPT 964/4885ALDH1A1 1466/4885KDM4E 2342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.